文章核心观点 - 帕西西亚治疗公司宣布任命詹姆斯·李博士加入科学顾问委员会，以指导PAS - 004治疗ETS2通路炎症性疾病的开发 [1] 公司动态 - 帕西西亚治疗公司宣布任命詹姆斯·李博士加入科学顾问委员会，指导PAS - 004治疗包括炎症性肠病、溃疡性结肠炎等在内的ETS2通路炎症性疾病 [1] - 公司计划通过非稀释性融资（包括赠款和/或战略合作）为PAS - 004在NF1以外的其他适应症的开发提供资金 [3] 人物信息 - 詹姆斯·李博士是2024年《自然》杂志一篇论文的主要作者，该论文确定ETS2是炎症性肠病等疾病中巨噬细胞驱动炎症的核心调节因子，且MEK抑制剂是最能有效抑制ETS2驱动炎症的药物类别 [2] - 詹姆斯·李博士是弗朗西斯·克里克研究所临床科学家小组组长和皇家自由医院名誉顾问胃肠病学家，在炎症性肠病方面有临床专长，是英国和国际炎症性肠病遗传学联盟的活跃成员 [3] - 詹姆斯·李博士曾在牛津、剑桥和哈佛接受培训，领导一个研究小组，致力于将基因关联转化为对自身免疫和炎症性疾病生物学的更好理解，其研究成果在《自然》和《细胞》等科学期刊上发表 [4] 公司概况 - 帕西西亚治疗公司是一家临床阶段的生物技术公司，主要专注于其主要候选药物PAS - 004的研发，该药物是用于治疗RAS病、MAPK通路驱动的肿瘤和其他疾病的下一代大环MEK抑制剂 [5] - 公司目前正在对PAS - 004进行两项临床试验，分别是针对晚期癌症患者的1期临床试验（NCT06299839）和针对1型神经纤维瘤病（NF1）相关丛状神经纤维瘤成年患者的1/1b期临床试验（NCT06961565） [5]

-- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated melanoma, who had progressed after two prior lines of therapy, including a prior MEK inhibitor + BRAF inhibitor combination therapy, achieves over 5 months of stable disease with tumor volume reduction of -14.9% and remains on treatment -- -- PAS-004 pharmacokinetics profile potentially supports a prolonge ...

-- Demonstrates PAS-004’s potential as a differentiated MEK inhibitor for immune-mediated inflammatory diseases such as IBD and ankylosing spondylitis – -- Positions PAS-004 for potential expansion beyond MAPK pathway driven tumors into inflammatory diseases – -- PAS-004 outperforms FDA-approved MEK inhibitor selumetinib in targeting ETS2 pathway – -- Study conducted at Francis Crick Institute by lead author of 2024 Nature paper that identified ETS2 as a central regulator of macrophage-driven Inflammation i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______to ________. Commission file number: 001-40804 PASITHEA THERAPEUTICS CORP. (Exact name of Registrant as specified in its charter) | Delaware | 85-1591963 | | --- | ...

-- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and cutaneous neurofibromas ---- Starting dose of 4mg tablet QD (once daily) ---- First trial site in Australia. Four additional sites planned for Australia, South Korea, and U.S. –-- Australian R&D Tax Incentive refund of up to 48.5% of eligible study-related costs expected -- MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- ...

MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics, Corp. (“Pasithea,” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced the closing of its previously announced public offering of 3,571,428 shares of its common stock (or pre-funded warrants in lieu thereof) and accompanying Series C warrants to purchase up ...

文章核心观点 - 临床阶段生物技术公司Pasithea Therapeutics宣布公开发行股票及认股权证定价，预计募资约500万美元用于公司业务发展 [1][4] 公司概况 - Pasithea是临床阶段生物技术公司，专注中枢神经系统疾病、RASopathies和MAPK通路驱动肿瘤创新疗法的发现、研究和开发 [7] 发行情况 - 公司公开发行3571428股普通股（或预融资认股权证），同时发行C类认股权证和D类认股权证，分别可购买最多3571428股普通股，组合发行价为每股普通股（或每份预融资认股权证）及附带认股权证1.40美元 [1] - C类普通股认股权证行使价为每股1.40美元，发行后可行使，五年后到期；D类普通股认股权证行使价为每股1.40美元，发行后可行使，18个月后到期 [2] - 发行预计于2025年5月7日左右完成，需满足惯常成交条件 [2] - H.C. Wainwright & Co.担任此次发行的独家配售代理 [3] 募资用途 - 发行毛收入预计约500万美元，扣除配售代理费和其他发行费用后，公司拟将净收入用于一般公司用途，包括正在进行的研究和临床前研究、临床试验、新生物和制药技术开发等 [4] 发行相关文件 - 上述证券根据2025年5月1日向美国证券交易委员会提交并于5月6日生效的S - 1表格注册声明发售，仅通过招股说明书进行发售，初步招股说明书已提交给美国证券交易委员会 [5] 公司联系方式 - 公司企业传播联系人是Patrick Gaynes，邮箱为pgaynes@pasithea.com [10]

-- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable disease with tumor volume reduction of -9.8% -- MIAMI, May 06, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 ...

MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004. “We are pleased to have recruited, enrolled and commenc ...

MIAMI, April 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) taking place May 30 – June 3, 2025, in Chicago, Ill ...